Figure 6: Relative cytotoxic anti-neoplastic potency of griseofulvin functioning as a tubulin/microtubule inhibitor against chemotherapeutic-resistant mammary adenocarcinoma as a function of challenge duration. Legend: (■) griseofulvin following an incubation period of 182-hours, and (♦) griseofulvin following an incubation period of 72-hours. Mammary adenocarcinoma SKBr-3 monolayer populations were incubated with covalent gemcitabine immunochemotherapeutics. Cytotoxicity was measured applying the MTT cell vitality assay relative to matched negative reference controls.